Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03118479 · ClinicalTrials.gov registry record · Phase 1

Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)

A Phase 1 study, sponsored by Massachusetts General Hospital.

Terminated
Registry status
Phase 1
Development phase
7
Enrollment target

NCT03118479: Clinical Trial Phase 1 study, sponsored by Massachusetts General Hospital.

NCT03118479 is a Phase 1 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03118479, a Phase 1 study, was terminated before completion, sponsored by Massachusetts General Hospital.

TERMINATED
Registry status
Phase 1
Development phase
7 participants
Enrollment target

Study Summary

The investigators are doing this research study to look at the relationship between testosterone (the main sex hormone in men) and insulin (the hormone that controls blood sugar levels) in men with Idiopathic Hypogonadotropic Hypogonadism (IHH). The investigators hypothesize that normalizing testosterone levels in men with IHH enhances insulin sensitivity, reduces visceral fat, increases lean body mass, and improves the lipid profile.

Interventions

  • DRUG Testosterone
  • DRUG Placebo Oral Tablet
  • DRUG Anastrozole Pill

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2010-05
Est. Completion 2010-09-01
Phase Phase 1

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT03118479

The ClinicalTrials.gov registry entry for NCT03118479 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Testosterone is the first listed.

NCT03118479 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03118479 about?

NCT03118479 is a clinical study titled "Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)". The investigators are doing this research study to look at the relationship between testosterone (the main sex hormone in men) and insulin (the hormone that controls blood sugar levels) in men with Idiopathic Hypogonadotropic Hypogonadism (IHH). The investigators hypothesize that normalizing testos...

What is the current status of trial NCT03118479?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2010-05. Estimated completion is 2010-09-01.

What interventions are being tested in trial NCT03118479?

The interventions under investigation include: Testosterone (DRUG), Placebo Oral Tablet (DRUG), Anastrozole Pill (DRUG).

Who is sponsoring clinical trial NCT03118479?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.